Highlights TG Therapeutics, Inc.

Equities

TGTX

US88322Q1085

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-17 pm EDT			5-day change	1st Jan Change
16.48 ^USD	-5.40%		-0.84%	-3.51%

May. 01	Wall Street Set to Open Lower Ahead of Fed Rate Decision; Private Employment Figures Top Forecasts	MT
May. 01	Transcript : TG Therapeutics, Inc., Q1 2024 Earnings Call, May 01, 2024

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Earnings Flash (TGTX) TG THERAPEUTICS Reports Q1 Revenue $63.5M, vs. Street Est of $54.6M	May. 01	MT
TG Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 01	CI
Sector Update: Health Care Stocks Mixed in Late Afternoon Trading	Apr. 18	MT
Sector Update: Health Care	Apr. 18	MT
TG Therapeutics Wins Veterans Affairs Contract for Multiple Sclerosis Drug Briumvi	Apr. 18	MT
Tg Therapeutics, Inc. Awards National Contract by the Department of Veterans Affairs for Briumvi as the Preferred Anti-Cd20 for Relapsing Forms of Multiple Sclerosis	Apr. 18	CI
TG Therapeutics Narrows Q4 Net Loss, Revenue Jumps; Shares Surge	Feb. 28	MT
TG Therapeutics Narrows Q4 Net Loss, Revenue Jumps; Shares Surging in Pre-Trade	Feb. 28	MT
Earnings Flash (TGTX) TG THERAPEUTICS Posts Q4 Revenue $44M, vs. Street Est of $40.1M	Feb. 28	MT
TG Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 28	CI
TG Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 28	CI
TG Therapeutics to Receive $12.5 Million Milestone Payment for Launch of Briumvi in Europe	Feb. 26	MT
TG Therapeutics Acquires Worldwide License to Precision BioSciences' Allogeneic CD19 CAR T Cell Therapy Program	Jan. 09	MT
Precision BioSciences Completes License Deal with TG Therapeutics for Cell Therapy Azer-Cel in Treatment of Autoimmune Diseases	Jan. 09	CI
Earnings Flash (TGTX) TG THERAPEUTICS Posts Q3 Revenue $165.8M, vs. Street Est of $63.3M	Nov. 01	MT
TG Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 01	CI
TG Therapeutics Signs $645 Million Sales Deal With Neuraxpharm for Briumvi	23-08-01	MT
Earnings Flash (TGTX) TG THERAPEUTICS Posts Q2 Revenue $16.1M, vs. Street Est of $17.9M	23-08-01	MT
TG Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-01	CI
TG Therapeutics, Inc. and Neuraxpharm Group Announce Ex-US Commercialization Agreement for BRIUMVI®? (ublituximab-xiiy)	23-08-01	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights TG Therapeutics, Inc.

Equities

TGTX

US88322Q1085

Highlights

Filters